Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death

BACKGROUND: Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The effects of add-on sotatercept in patients with advanced pulmonary arterial hypertension and a high risk of death are unclear. METHODS: In this phase 3 trial, we randomly assigned patients with pulmonary arterial hypertension (WHO functional class III or IV) and a high 1-year risk of death (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management Lite 2 risk score,

• Humbert, M.
• McLaughlin, V. V.
• Badesch, D. B.
• Ghofrani, H. A.
• Gibbs, J. S. R.
• Gomberg-Maitland, M.
• Preston, I. R.
• Souza, R.
• Waxman, A. B.
• Moles, V. M.
• Savale, L.
• Vizza, C. D.
• Rosenkranz, S.
• Shi, Y.
• Miller, B.
• Mackenzie, H. S.
• Kim, S. S.
• Loureiro, M. J.
• Patel, M. J.
• Koglin, J.
• Cornell, A. G.
• Hoeper, M. M.